Request Appointment
161 Fort Washington AveNew York, NY 10032
Fax+1 212-305-0129
Overview of Dr. McKiernan
Dr. James McKiernan is an urologist in New York, NY and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital, NewYork-Presbyterian/Columbia University Irving Medical Center, and NewYork-Presbyterian/Allen Hospital. He received his medical degree from Columbia University Vagelos College of Physicians and Surgeons and has been in practice 33 years. He is one of 199 doctors at New York-Presbyterian Hospital and one of 6 doctors at NewYork-Presbyterian/Allen Hospital who specialize in Urology. He has more than 100 publications and over 500 citings.
Education & Training
New York Presbyterian Hospital (Cornell Campus)Residency, Urology, 1995 - 1999- New York Presbyterian Hospital (Columbia Campus)Residency, Surgery, 1993 - 1995
Columbia University Vagelos College of Physicians and SurgeonsClass of 1993
Johns Hopkins UniversityB.A., Biology, 1989
Certifications & Licensure
FL State Medical License 2021 - Present
NJ State Medical License 2021 - 2027
NY State Medical License 1996 - 2027
American Board of Urology Urology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification Allscripts TouchWorks EHR, Allscripts, 2013-2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2013-2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification Allscripts TouchWorks EHR (Complete), Allscripts, 2013-2014, 2016-2017
Clinical Trials
- Intravesicular Abraxane for Treatment-Refractory Bladder Cancer
- Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer Start of enrollment: 2014 Mar 01
- Phase 1/2 Study of ABI-009 in Nonmuscle Invasive Bladder Cancer Start of enrollment: 2014 Apr 09
Publications & Presentations
PubMed
- Neoadjuvant Fc-enhanced anti-CTLA-4 targets Tregs to augment androgen deprivation in high-risk prostate cancer: A randomized phase I trial.Casey R Ager, Aleksandar Obradovic, Patrick McCann, Matthew Chaimowitz, Alexander L E Wang
Cell Reports. Medicine. 2026-03-17 - Revisiting BCG: The potential of rescue BCG therapy for BCG-unresponsive non-muscle-invasive bladder cancer.Ketty Bai, Srinath-Reddi Pingle, Rainjade Chung, Benjamin I Joffe, Caroline Laplaca
Urologic Oncology. 2026-01-01 - Combination regimen of intravesical docetaxel, gemcitabine, and cisplatin in patients with BCG-unresponsive bladder cancer: clinical outcomes and genomic correlations.Benjamin I Joffe, John R Christin, Clémentine Le Coz, Prakash Gorroochurn, Jamie S Pak
Urologic Oncology. 2025-10-01
Journal Articles
- Impact of synchronous metastasis distribution on cancer-specific survival in renal cell carcinoma after radical nephrectomy with tumor thrombectomyTilki D, Hu B, Nguyen HG, Dall'Era MA, Bertini R, Carballido JA, Chandrasekar T, Chromecki T, Ciancio G, Daneshmand S, Gontero P, Gonzalez J, Haferkamp A, Hohenfellner..., Urol, 7/22/2014
- Cost-effectiveness of neoadjuvant chemotherapy before radical cystectomy for muscle-invasive bladder cancerStevenson SM, Danzig MR, Ghandour RA, Deibert CM, Joel Decastro G, Benson MC, McKiernan JM, Urol Oncol, 7/3/2014
- Phase II Trial of Intravesical Nanoparticle Albumin-Bound (nab-) Paclitaxel for the Treatment of Non-Muscle Invasive Urothelial Carcinoma of the Bladder after BCG Trea...McKiernan JM, Holder DD, Ghandour RA, Barlow LJ, Ahn JJ, Kates M, Badalato GM, Roychoudhury A, Decastro GJ, Benson MC, J Urol, 7/1/2014
Books/Book Chapters
Authored Content
- Is Imperative Partial Nephrectomy Feasible for Kidney Cancer with Venous Thrombus Involvement? Outcomes of 42 Cases and Matched Pair Analysis with a Large Radical Nephrectomy CohortMay 2018
- Is Imperative Partial Nephrectomy Feasible for Kidney Cancer with Venous Thrombus Involvement? Outcomes of 42 Cases and Matched Pair Analysis with a Large Radical Nephrectomy CohortMay 2018
- Is Imperative Partial Nephrectomy Feasible for Kidney Cancer with Venous Thrombus Involvement? Outcomes of 42 Cases and Matched Pair Analysis with a Large Radical Nephrectomy CohortMay 2018
Press Mentions
Columbia Medical School Freezes Hiring and Other Spending Amid Threat of Federal CutsFebruary 13th, 2025- New Treatment Options Emerging for Patients with Refractory NMIBCMay 13th, 2022
- Bio-Techne Announces Publication of ExoDx Prostate Test Study in Patients with Prior Negative Prostate BiopsySeptember 23rd, 2020
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
